Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 10 of 10 entries
Sorted by: Best Match Show Resources per page
[Mobile applications for French medical students: Work in progress].

Presse medicale (Paris, France : 1983)

Vignot S, Servagi-Vernat S, Brouard B, Merrouche Y.
PMID: 28919274
Presse Med. 2017 Nov;46(11):1110-1112. doi: 10.1016/j.lpm.2017.08.005. Epub 2017 Sep 14.

No abstract available.

Cite
Vignot S, Servagi-Vernat S, Brouard B, et al. Applications mobiles pour la préparation de l’ECN : une offre en construction. [Mobile applications for French medical students: Work in progress]. Presse Med. 2017;46(11):1110-1112doi: 10.1016/j.lpm.2017.08.005.
Vignot, S., Servagi-Vernat, S., Brouard, B., & Merrouche, Y. (2017). Applications mobiles pour la préparation de l’ECN : une offre en construction. [Mobile applications for French medical students: Work in progress]. Presse medicale (Paris, France : 1983), 46(11), 1110-1112. https://doi.org/10.1016/j.lpm.2017.08.005
Vignot, Stéphane, et al. "Applications mobiles pour la préparation de l’ECN : une offre en construction." [Mobile applications for French medical students: Work in progress]. Presse medicale (Paris, France : 1983) vol. 46,11 (2017): 1110-1112. doi: https://doi.org/10.1016/j.lpm.2017.08.005
Vignot S, Servagi-Vernat S, Brouard B, Merrouche Y. Applications mobiles pour la préparation de l’ECN : une offre en construction. [Mobile applications for French medical students: Work in progress]. Presse Med. 2017 Nov;46(11):1110-1112. doi: 10.1016/j.lpm.2017.08.005. Epub 2017 Sep 14. French. PMID: 28919274.
Copy Download .nbib Format: NLM
Cystic brain metastasis from prostate cancer: A case report and literature review.

Urology case reports

Marchand Crety C, Ettalhaoui L, Servagi Vernat S.
PMID: 32382510
Urol Case Rep. 2020 Apr 22;32:101219. doi: 10.1016/j.eucr.2020.101219. eCollection 2020 Sep.

Parenchymal brain metastases from prostate cancer are rare and mostly appear in the terminal phase of the disease. Here, we report a case of cystic cerebral metastases in patient with prostate adenocarcinoma. This patient presented with one large parietal...

Cite
Marchand Crety C, Ettalhaoui L, Servagi Vernat S. Cystic brain metastasis from prostate cancer: A case report and literature review. Urol Case Rep. 2020;32:101219doi: 10.1016/j.eucr.2020.101219.
Marchand Crety, C., Ettalhaoui, L., & Servagi Vernat, S. (2020). Cystic brain metastasis from prostate cancer: A case report and literature review. Urology case reports, 32101219. https://doi.org/10.1016/j.eucr.2020.101219
Marchand Crety, Charles, et al. "Cystic brain metastasis from prostate cancer: A case report and literature review." Urology case reports vol. 32 (2020): 101219. doi: https://doi.org/10.1016/j.eucr.2020.101219
Marchand Crety C, Ettalhaoui L, Servagi Vernat S. Cystic brain metastasis from prostate cancer: A case report and literature review. Urol Case Rep. 2020 Apr 22;32:101219. doi: 10.1016/j.eucr.2020.101219. eCollection 2020 Sep. PMID: 32382510; PMCID: PMC7201187.
Copy Download .nbib Format: NLM
Impact of Neck Dissection in Head and Neck Squamous Cell Carcinomas of Unknown Primary.

Cancers

Abu-Shama Y, Salleron J, Carsuzaa F, Sun XS, Pflumio C, Troussier I, Petit C, Caubet M, Beddok A, Calugaru V, Servagi-Vernat S, Castelli J, Miroir J, Krengli M, Giraud P, Romano E, Khalifa J, Doré M, Blanchard N, Coutte A, Dupin C, Sumodhee S, Tao Y, Roth V, Geoffrois L, Toussaint B, Nguyen DT, Faivre JC, Thariat J.
PMID: 34067697
Cancers (Basel). 2021 May 17;13(10). doi: 10.3390/cancers13102416.

PURPOSE: Management of head and neck cancers of unknown primary (HNCUP) combines neck dissection (ND) and radiotherapy, with or without chemotherapy. The prognostic value of ND has hardly been studied in HNCUP.METHODS: A retrospective multicentric study assessed the impact...

Cite
Abu-Shama Y, Salleron J, Carsuzaa F, et al. Impact of Neck Dissection in Head and Neck Squamous Cell Carcinomas of Unknown Primary. Cancers (Basel). 2021;13(10)doi: 10.3390/cancers13102416.
Abu-Shama, Y., Salleron, J., Carsuzaa, F., Sun, X. S., Pflumio, C., Troussier, I., Petit, C., Caubet, M., Beddok, A., Calugaru, V., Servagi-Vernat, S., Castelli, J., Miroir, J., Krengli, M., Giraud, P., Romano, E., Khalifa, J., Doré, M., Blanchard, N., Coutte, A., Dupin, C., Sumodhee, S., Tao, Y., Roth, V., Geoffrois, L., Toussaint, B., Nguyen, D. T., Faivre, J. C., & Thariat, J. (2021). Impact of Neck Dissection in Head and Neck Squamous Cell Carcinomas of Unknown Primary. Cancers, 13(10), . https://doi.org/10.3390/cancers13102416
Abu-Shama, Yazan, et al. "Impact of Neck Dissection in Head and Neck Squamous Cell Carcinomas of Unknown Primary." Cancers vol. 13,10 (2021). doi: https://doi.org/10.3390/cancers13102416
Abu-Shama Y, Salleron J, Carsuzaa F, Sun XS, Pflumio C, Troussier I, Petit C, Caubet M, Beddok A, Calugaru V, Servagi-Vernat S, Castelli J, Miroir J, Krengli M, Giraud P, Romano E, Khalifa J, Doré M, Blanchard N, Coutte A, Dupin C, Sumodhee S, Tao Y, Roth V, Geoffrois L, Toussaint B, Nguyen DT, Faivre JC, Thariat J. Impact of Neck Dissection in Head and Neck Squamous Cell Carcinomas of Unknown Primary. Cancers (Basel). 2021 May 17;13(10). doi: 10.3390/cancers13102416. PMID: 34067697; PMCID: PMC8156697.
Copy Download .nbib Format: NLM
Histosurgical mapping of endoscopic endonasal surgery of sinonasal tumours to improve radiotherapy guidance.

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique

Leleu T, Bastit V, Doré M, Kammerer E, Florescu C, Alfonsi M, Troussier I, Bensadoun RJ, Biau J, Blais E, Coutte A, Deberne M, Wiazzane N, Dupin C, Faivre JC, Giraud P, Graff P, Guihard S, Huguet F, Janoray G, Liem X, Pointreau Y, Racadot S, Schick U, Servagi-Vernat S, Sun XS, Thureau S, Villa J, Vulquin N, Wong S, Patron V, Thariat J.
PMID: 34175228
Cancer Radiother. 2021 Jun 23; doi: 10.1016/j.canrad.2021.06.014. Epub 2021 Jun 23.

PURPOSE: Endoscopic endonasal surgery (EES) is becoming a standard for most malignant sinonasal tumours. Margin analysis after piecemeal resection is complex and optimally relies on accurate histosurgical mapping. Postoperative radiotherapy may be adapted based on margin assessment mapping to...

Cite
Leleu T, Bastit V, Doré M, et al. Histosurgical mapping of endoscopic endonasal surgery of sinonasal tumours to improve radiotherapy guidance. Cancer Radiother. 2021;doi: 10.1016/j.canrad.2021.06.014.
Leleu, T., Bastit, V., Doré, M., Kammerer, E., Florescu, C., Alfonsi, M., Troussier, I., Bensadoun, R. J., Biau, J., Blais, E., Coutte, A., Deberne, M., Wiazzane, N., Dupin, C., Faivre, J. C., Giraud, P., Graff, P., Guihard, S., Huguet, F., Janoray, G., Liem, X., Pointreau, Y., Racadot, S., Schick, U., Servagi-Vernat, S., Sun, X. S., Thureau, S., Villa, J., Vulquin, N., Wong, S., Patron, V., & Thariat, J. (2021). Histosurgical mapping of endoscopic endonasal surgery of sinonasal tumours to improve radiotherapy guidance. Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique, . https://doi.org/10.1016/j.canrad.2021.06.014
Leleu, T, et al. "Histosurgical mapping of endoscopic endonasal surgery of sinonasal tumours to improve radiotherapy guidance." Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique vol. (2021). doi: https://doi.org/10.1016/j.canrad.2021.06.014
Leleu T, Bastit V, Doré M, Kammerer E, Florescu C, Alfonsi M, Troussier I, Bensadoun RJ, Biau J, Blais E, Coutte A, Deberne M, Wiazzane N, Dupin C, Faivre JC, Giraud P, Graff P, Guihard S, Huguet F, Janoray G, Liem X, Pointreau Y, Racadot S, Schick U, Servagi-Vernat S, Sun XS, Thureau S, Villa J, Vulquin N, Wong S, Patron V, Thariat J. Histosurgical mapping of endoscopic endonasal surgery of sinonasal tumours to improve radiotherapy guidance. Cancer Radiother. 2021 Jun 23; doi: 10.1016/j.canrad.2021.06.014. Epub 2021 Jun 23. PMID: 34175228.
Copy Download .nbib Format: NLM
Age, Neurological Status MRC Scale, and Postoperative Morbidity are Prognostic Factors in Patients with Glioblastoma Treated by Chemoradiotherapy.

Clinical Medicine Insights. Oncology

Verlut C, Mouillet G, Magnin E, Buffet-Miny J, Viennet G, Cattin F, Billon-Grand NC, Bonnet E, Servagi-Vernat S, Godard J, Billon-Grand R, Petit A, Moulin T, Cals L, Pivot X, Curtit E.
PMID: 27559302
Clin Med Insights Oncol. 2016 Aug 17;10:77-82. doi: 10.4137/CMO.S38474. eCollection 2016.

INTRODUCTION: Temozolomide and concomitant radiotherapy followed by temozolomide has been used as a standard therapy for the treatment of newly diagnosed glioblastoma multiform since 2005. A search for prognostic factors was conducted in patients with glioblastoma routinely treated by...

Cite
Verlut C, Mouillet G, Magnin E, et al. Age, Neurological Status MRC Scale, and Postoperative Morbidity are Prognostic Factors in Patients with Glioblastoma Treated by Chemoradiotherapy. Clin Med Insights Oncol. 2016;10:77-82doi: 10.4137/CMO.S38474.
Verlut, C., Mouillet, G., Magnin, E., Buffet-Miny, J., Viennet, G., Cattin, F., Billon-Grand, N. C., Bonnet, E., Servagi-Vernat, S., Godard, J., Billon-Grand, R., Petit, A., Moulin, T., Cals, L., Pivot, X., & Curtit, E. (2016). Age, Neurological Status MRC Scale, and Postoperative Morbidity are Prognostic Factors in Patients with Glioblastoma Treated by Chemoradiotherapy. Clinical Medicine Insights. Oncology, 1077-82. https://doi.org/10.4137/CMO.S38474
Verlut, Clotilde, et al. "Age, Neurological Status MRC Scale, and Postoperative Morbidity are Prognostic Factors in Patients with Glioblastoma Treated by Chemoradiotherapy." Clinical Medicine Insights. Oncology vol. 10 (2016): 77-82. doi: https://doi.org/10.4137/CMO.S38474
Verlut C, Mouillet G, Magnin E, Buffet-Miny J, Viennet G, Cattin F, Billon-Grand NC, Bonnet E, Servagi-Vernat S, Godard J, Billon-Grand R, Petit A, Moulin T, Cals L, Pivot X, Curtit E. Age, Neurological Status MRC Scale, and Postoperative Morbidity are Prognostic Factors in Patients with Glioblastoma Treated by Chemoradiotherapy. Clin Med Insights Oncol. 2016 Aug 17;10:77-82. doi: 10.4137/CMO.S38474. eCollection 2016. PMID: 27559302; PMCID: PMC4990148.
Copy Download .nbib Format: NLM
Efficacy of trabectedin in metastatic solitary fibrous tumor.

Rare tumors

Chaigneau L, Kalbacher E, Thiery-Vuillemin A, Fagnoni-Legat C, Isambert N, Aherfi L, Pauchot J, Delroeux D, Servagi-Vernat S, Mansi L, Pivot X.
PMID: 22066036
Rare Tumors. 2011 Jul 11;3(3):e29. doi: 10.4081/rt.2011.e29. Epub 2011 Jul 18.

Solitary fibrous tumor is a rare tumor type and has an unpredictable course. Local recurrence rate varies between 9 and 19%, and rate of metastatic involvement between 0 and 36 %. It is characterized by a typical architecture and...

Cite
Chaigneau L, Kalbacher E, Thiery-Vuillemin A, et al. Efficacy of trabectedin in metastatic solitary fibrous tumor. Rare Tumors. 2011;3(3):e29doi: 10.4081/rt.2011.e29.
Chaigneau, L., Kalbacher, E., Thiery-Vuillemin, A., Fagnoni-Legat, C., Isambert, N., Aherfi, L., Pauchot, J., Delroeux, D., Servagi-Vernat, S., Mansi, L., & Pivot, X. (2011). Efficacy of trabectedin in metastatic solitary fibrous tumor. Rare tumors, 3(3), e29. https://doi.org/10.4081/rt.2011.e29
Chaigneau, Loïc, et al. "Efficacy of trabectedin in metastatic solitary fibrous tumor." Rare tumors vol. 3,3 (2011): e29. doi: https://doi.org/10.4081/rt.2011.e29
Chaigneau L, Kalbacher E, Thiery-Vuillemin A, Fagnoni-Legat C, Isambert N, Aherfi L, Pauchot J, Delroeux D, Servagi-Vernat S, Mansi L, Pivot X. Efficacy of trabectedin in metastatic solitary fibrous tumor. Rare Tumors. 2011 Jul 11;3(3):e29. doi: 10.4081/rt.2011.e29. Epub 2011 Jul 18. PMID: 22066036; PMCID: PMC3208416.
Copy Download .nbib Format: NLM
Defining preoperative treatment strategies in t3 rectal cancer.

Gastrointestinal cancer research : GCR

Bosset JF, Bosset M, Nguyen F, Servagi-Vernat S, Sedrati A.
PMID: 19343151
Gastrointest Cancer Res. 2008 Jul;2(4):S54-7.

Preoperative treatments for patients with T3 rectal cancer have significantly improved local recurrence rates, while survival outcomes have not changed significantly relative to those achieved with surgery alone. The prognosis of patients with T3 tumors, however, is heterogeneous; therapy...

Cite
Bosset JF, Bosset M, Nguyen F, et al. Defining preoperative treatment strategies in t3 rectal cancer. Gastrointest Cancer Res. 2008;2(4):S54-7
Bosset, J. F., Bosset, M., Nguyen, F., Servagi-Vernat, S., & Sedrati, A. (2008). Defining preoperative treatment strategies in t3 rectal cancer. Gastrointestinal cancer research : GCR, 2(4), S54-7.
Bosset, Jean-François, et al. "Defining preoperative treatment strategies in t3 rectal cancer." Gastrointestinal cancer research : GCR vol. 2,4 (2008): S54-7.
Bosset JF, Bosset M, Nguyen F, Servagi-Vernat S, Sedrati A. Defining preoperative treatment strategies in t3 rectal cancer. Gastrointest Cancer Res. 2008 Jul;2(4):S54-7. PMID: 19343151; PMCID: PMC2661540.
Copy Download .nbib Format: NLM
Factors associated with inoperable cutaneous squamous cell carcinoma.

European journal of dermatology : EJD

Petit A, Hourbeigt K, Servagi-Vernat S, Visseaux L, Grange F.
PMID: 34309524
Eur J Dermatol. 2021 Jun 01;31(3):396-402. doi: 10.1684/ejd.2021.4048.

Inoperable cutaneous squamous cell carcinomas (SCCs) are rare and life-threatening, but few studies have investigated their causal factors. Our aim was to determine factors associated with inoperable SCCs, as well as patient and tumour characteristics, and care pathway-related factors....

Cite
Petit A, Hourbeigt K, Servagi-Vernat S, et al. Factors associated with inoperable cutaneous squamous cell carcinoma. Eur J Dermatol. 2021;31(3):396-402doi: 10.1684/ejd.2021.4048.
Petit, A., Hourbeigt, K., Servagi-Vernat, S., Visseaux, L., & Grange, F. (2021). Factors associated with inoperable cutaneous squamous cell carcinoma. European journal of dermatology : EJD, 31(3), 396-402. https://doi.org/10.1684/ejd.2021.4048
Petit, Alix, et al. "Factors associated with inoperable cutaneous squamous cell carcinoma." European journal of dermatology : EJD vol. 31,3 (2021): 396-402. doi: https://doi.org/10.1684/ejd.2021.4048
Petit A, Hourbeigt K, Servagi-Vernat S, Visseaux L, Grange F. Factors associated with inoperable cutaneous squamous cell carcinoma. Eur J Dermatol. 2021 Jun 01;31(3):396-402. doi: 10.1684/ejd.2021.4048. PMID: 34309524.
Copy Download .nbib Format: NLM
Predictive Value of Early Post-Treatment Diffusion-Weighted MRI for Recurrence or Tumor Progression of Head and Neck Squamous Cell Carcinoma Treated with Chemo-Radiotherapy.

Cancers

Brenet E, Barbe C, Hoeffel C, Dubernard X, Merol JC, Fath L, Servagi-Vernat S, Labrousse M.
PMID: 32422975
Cancers (Basel). 2020 May 14;12(5). doi: 10.3390/cancers12051234.

AIMS: To investigate the predictive capacity of early post-treatment diffusion-weighted magnetic resonance imaging (MRI) for recurrence or tumor progression in patients with no tumor residue after chemo-radiotherapy (CRT) for head and neck squamous cell carcinoma, and, to assess the...

Cite
Brenet E, Barbe C, Hoeffel C, et al. Predictive Value of Early Post-Treatment Diffusion-Weighted MRI for Recurrence or Tumor Progression of Head and Neck Squamous Cell Carcinoma Treated with Chemo-Radiotherapy. Cancers (Basel). 2020;12(5)doi: 10.3390/cancers12051234.
Brenet, E., Barbe, C., Hoeffel, C., Dubernard, X., Merol, J. C., Fath, L., Servagi-Vernat, S., & Labrousse, M. (2020). Predictive Value of Early Post-Treatment Diffusion-Weighted MRI for Recurrence or Tumor Progression of Head and Neck Squamous Cell Carcinoma Treated with Chemo-Radiotherapy. Cancers, 12(5), . https://doi.org/10.3390/cancers12051234
Brenet, Esteban, et al. "Predictive Value of Early Post-Treatment Diffusion-Weighted MRI for Recurrence or Tumor Progression of Head and Neck Squamous Cell Carcinoma Treated with Chemo-Radiotherapy." Cancers vol. 12,5 (2020). doi: https://doi.org/10.3390/cancers12051234
Brenet E, Barbe C, Hoeffel C, Dubernard X, Merol JC, Fath L, Servagi-Vernat S, Labrousse M. Predictive Value of Early Post-Treatment Diffusion-Weighted MRI for Recurrence or Tumor Progression of Head and Neck Squamous Cell Carcinoma Treated with Chemo-Radiotherapy. Cancers (Basel). 2020 May 14;12(5). doi: 10.3390/cancers12051234. PMID: 32422975; PMCID: PMC7281260.
Copy Download .nbib Format: NLM
10-Year Locoregional Control with Postoperative External Beam Radiotherapy in Patients with Locally Advanced High-Risk Non-Anaplastic Thyroid Carcinoma De Novo or at Relapse, a Propensity Score Analysis.

Cancers

Servagi Vernat S, Khalifa J, Sun XS, Kammerer E, Blais E, Faivre JC, Sio TT, Pan J, Qiu H, Bar-Sela G, Simon JM, Salleron J, Thariat J.
PMID: 31248183
Cancers (Basel). 2019 Jun 19;11(6). doi: 10.3390/cancers11060849.

(1) Background: To assess the role of postoperative external beam radiotherapy (pEBRT) on locoregional failure (LRF) for patients with locally advanced high-risk non-anaplastic thyroid carcinoma (naTC) at primary event or relapse. (2) Methods: Between 1995 and 2015, postoperative naTC...

Cite
Servagi Vernat S, Khalifa J, Sun XS, et al. 10-Year Locoregional Control with Postoperative External Beam Radiotherapy in Patients with Locally Advanced High-Risk Non-Anaplastic Thyroid Carcinoma De Novo or at Relapse, a Propensity Score Analysis. Cancers (Basel). 2019;11(6)doi: 10.3390/cancers11060849.
Servagi Vernat, S., Khalifa, J., Sun, X. S., Kammerer, E., Blais, E., Faivre, J. C., Sio, T. T., Pan, J., Qiu, H., Bar-Sela, G., Simon, J. M., Salleron, J., & Thariat, J. (2019). 10-Year Locoregional Control with Postoperative External Beam Radiotherapy in Patients with Locally Advanced High-Risk Non-Anaplastic Thyroid Carcinoma De Novo or at Relapse, a Propensity Score Analysis. Cancers, 11(6), . https://doi.org/10.3390/cancers11060849
Servagi Vernat, Stéphanie, et al. "10-Year Locoregional Control with Postoperative External Beam Radiotherapy in Patients with Locally Advanced High-Risk Non-Anaplastic Thyroid Carcinoma De Novo or at Relapse, a Propensity Score Analysis." Cancers vol. 11,6 (2019). doi: https://doi.org/10.3390/cancers11060849
Servagi Vernat S, Khalifa J, Sun XS, Kammerer E, Blais E, Faivre JC, Sio TT, Pan J, Qiu H, Bar-Sela G, Simon JM, Salleron J, Thariat J. 10-Year Locoregional Control with Postoperative External Beam Radiotherapy in Patients with Locally Advanced High-Risk Non-Anaplastic Thyroid Carcinoma De Novo or at Relapse, a Propensity Score Analysis. Cancers (Basel). 2019 Jun 19;11(6). doi: 10.3390/cancers11060849. PMID: 31248183; PMCID: PMC6628348.
Copy Download .nbib Format: NLM
Showing 1 to 10 of 10 entries